{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Not able to obtain outcome data.","groups":[{"description":"Azacitidine will be administered to all the patients subcutaneously at a dose of 75 mg/m2 daily for five days(day 1-5). These cycles will be repeated at 28 day intervals depending on hematopoietic recovery. Starting on day 6 patients will receive lenalidomide 15 mg PO daily until day 21. No drug will be administered from day 22 to day 28. Lymphapheresis will occur after cycles 2 and 3.Patients will undergo a stem cell collection approximately two weeks after complete myeloid recovery from the third cycle of therapy. Stem Cell Transplant (SCT) will occur per transplant center protocols. Post-transplant single or tandem autologous lymphocyte infusions (ALI) will be performed no earlier than 30 days post-transplant and no later than 40 days.","id":"OG000","title":"Aza Len Lymphapheresis SCT ALI"}],"populationDescription":"Not able to obtain outcome data. The lab doing this correlative analysis lost the personnel support to process the samples.","reportingStatus":"POSTED","timeFrame":"6 months","title":"Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)","type":"SECONDARY"}